Cytomegalovirus Retinitis Following Daratumumab for Multiple Myeloma: A Case Report and Literature Review

Introduction: Cytomegalovirus (CMV) retinitis typically occurs in patients with acquired immunodeficiency syndrome. It may also manifest in patients with hematological diseases, mostly after allogeneic hematopoietic cell transplantation. However, its incidence in multiple myeloma remains exceedingly rare, with only 15 reported cases in the literature. Case Report: A 71‐year‐old man diagnosed with multiple myeloma achieved complete response following treatment with daratumumab, lenalidomide, and dexamethasone. After 2 years of therapy, he developed CMV retinitis. Systemic antiviral treatment led to improved visual acuity, and antimyeloma treatment was successfully resumed with reduced intensity of chemotherapy. Conclusion: CMV reactivation is increasingly being reported with the development of new treatment strategies for multiple myeloma and is considered a significant drug‐related clinical complication. We reviewed previous reports and discussed the incidence and optimal management of CMV reactivation in this patient population.